Picture of AB Science SA logo

AB AB Science SA Share Price

0.000.00%
fr flag iconLast trade - 00:00
HealthcareHighly SpeculativeSmall CapSucker Stock

Momentum

Relative Strength (%)
1m-17.83%
3m-41.45%
6m-29.7%
1yr-70.9%
Volume Change (%)
10d/3m-54.35%
Price vs... (%)
52w High-69.91%
50d MA-23.57%
200d MA-33.13%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-128.84%
Return on Equityn/a
Operating Margin-1959.46%

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202331st Dec 2024
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2023 / 2024

Blurred out image of AB Science SA EPS forecast chart

Profile Summary

AB Science SA, also known as AB Science, is a France-based pharmaceutical company specialized in the research, discovery, development and marketing of protein kinase inhibitors (PKIs). It is engaged in targeted therapies through tyrosine kinase inhibitors for treating diseases with high medical factor in the field of cancer, chronic inflammatory diseases, neurological degenerative disorders and central nervous systems diseases in both human and veterinary medicine. The main focus of the Company is the development of tyrosine kinase inhibitors, for instance Masitinib which is a tyrosine kinase inhibitor used as a veterinary medicine in the treatment of canine mast cell tumors. The Company is present in the United States and Europe. As of December 31, 2013, the Company operated though a subsidiary, AB Science USA LCC, based in the United States.

Directors

Last Annual
December 31st, 2022
Last Interim
June 30th, 2023
Incorporated
July 3rd, 2001
Public Since
April 21st, 2010
No. of Employees
89
Sector
Pharmaceuticals
Industry
Healthcare
Exchange
fr flag iconEuronext - Paris
Shares in Issue
49,567,190

AB Share Price Performance

Upcoming Events for AB

Full Year 2023 AB Science SA Earnings Release

Ab Science SA Annual Shareholders Meeting

Half Year 2024 AB Science SA Earnings Release

Similar to AB

Picture of Advicenne SA logo

Advicenne SA

fr flag iconEuronext - Paris

Picture of Aelis Farma SA logo

Aelis Farma SA

fr flag iconEuronext - Paris

Picture of Boiron SA logo

Boiron SA

fr flag iconEuronext - Paris

Picture of DBV Technologies SA logo

DBV Technologies SA

fr flag iconEuronext - Paris

Picture of Elsalys Biotech SA logo

Elsalys Biotech SA

fr flag iconEuronext - Paris

FAQ